 After a manufacturer's appeal Regorafenib was restored to the list.Research indicates that society does not support the prioritisation of cancer drugs over other treatments.The Financial Times attacked the fund in December 2014 as "a populist gesture that gives the impression of benefiting patients, but in fact rewards poor quality drugs while benefiting a handful of pharmaceutical companies at the expense of the taxpayer and the full range of NHS patients", complaining that it undermined the National Institute for Health and Care Excellence.